Takeda’s Febuxostat Finally Gets Advisory Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The subject of FDA “approvable” letters in 2005 and 2006, the investigational gout drug won EU approval in May.
You may also be interested in...
Takeda’s Febuxostat Gets Advisory Committee Nod for Gout; Cardio Risk Remains A Concern
Committee members reach near-unanimous agreement to approve febuxostat for gout, but urge FDA to require post-approval cardiovascular studies.
Takeda’s Febuxostat Gets Advisory Committee Nod for Gout; Cardio Risk Remains A Concern
Committee members reach near-unanimous agreement to approve febuxostat for gout, but urge FDA to require post-approval cardiovascular studies.
Takeda Buys Abbott’s Stake In TAP Joint Venture
Japanese pharma establishes Takeda America Holdings, combining all of its U.S. subsidiaries.